One hundred seventy-two economies are now engaged in discussions to join the COVAX Facility, a global initiative aimed at working with vaccine manufacturers to secure equitable access to safe and effective COVID-19 vaccines once they receive regulatory approval.
As global initiatives work to ensure equitable access to COVID-19 vaccines, organizations are striving to secure sufficient doses and prevent supply hoarding. The COVAX initiative represents a multilateral effort to pool purchasing power and share manufacturing risks, ensuring that lower- and middle-income countries are not left behind in the distribution of eventual vaccines. Participating economies must finalize their commitments through binding agreements as deadlines approach in September and October 2020.
Pooling Resources to Prioritize Vulnerable Populations
- Equitable Distribution: The initiative pools resources from wealthy nations and international donors so that lower-income countries receive vaccine doses proportional to their populations, prioritizing healthcare workers and the elderly first.
- Diversified Portfolio: By backing multiple candidate vaccines, the program hedges against the high clinical failure rate inherent in early-stage vaccine development, maintaining the largest and most diverse COVID-19 vaccine portfolio in the world.
- At-Risk Manufacturing: Advance financial resources are allocated to expand production capabilities prior to the completion of clinical trials, enabling immediate widespread distribution once the inoculations are verified as safe and successful.
Maintaining the Largest Global Vaccine Portfolio
Led by Gavi, the Vaccine Alliance, the COVAX Facility constitutes a core component of the vaccines pillar within the Access to COVID-19 Tools (ACT) Accelerator—a worldwide partnership engaging developers to speed up the creation, manufacturing, and fair availability of COVID-19 diagnostic tests, medical treatments, and immunizations.
Among the CEPI-supported candidates are Phase III trials from Moderna in the United States and the AstraZeneca/University of Oxford collaboration in the United Kingdom. Early-stage trials include Inovio and Novavax in the United States, CureVac in Germany, and Clover Biopharmaceuticals in China. Portfolio diversification is essential because individual vaccines historically carry a high clinical failure rate, and the goal is to guarantee that safe and effective vaccines reach mass production.
| Candidate Developer | Country of Origin | Current Clinical Phase |
|---|---|---|
| AstraZeneca / University of Oxford | United Kingdom | Phase III |
| Moderna | United States | Phase III |
| Inovio | United States | Phase I/II |
| Novavax | United States | Phase I/II |
| CureVac | Germany | Phase I |
Meeting Strict Financial Deadlines for Participation
The operational success of the COVAX Facility depends heavily on strict financial timelines. Eighty higher-income economies, which will self-finance their vaccine doses through public budgets, submitted non-binding expressions of interest. These nations must confirm their intent to participate by August 31 and convert those expressions into binding commitments by September 18, with upfront payments due no later than October 9, 2020.
To support lower-income nations, Gavi launched the COVAX Advance Market Commitment (AMC), a specialized financing instrument. The AMC has raised over US$ 600 million toward an initial target of US$ 2 billion from sovereign donors, philanthropic organizations, and the private sector. A partnership between the Serum Institute of India, Gavi, and the Bill & Melinda Gates Foundation secured a commitment for up to 100 million doses of the AstraZeneca or Novavax candidate vaccines at just US$ 3 per dose for low- and middle-income economies.
Equal access to a COVID-19 vaccine is the key to beating the virus and paving the way for recovery from the pandemic.
Global Solidarity Versus Regional Nationalism
The overarching objective of the COVAX Facility is to deliver two billion doses of safe, effective vaccines by the end of 2021. Regulatory approval pathways will rely on stringent evaluations, such as WHO prequalification. Allocation frameworks formulated by the WHO will dictate distribution, initially targeting healthcare workers, the elderly, and individuals with pre-existing comorbidities before expanding outward.
Despite strong initial uptake representing over 70% of the world’s population across 172 participating economies, organizers note significant funding gaps. Sustained capitalization for the AMC is urgently needed to ensure that ability to pay does not dictate survival.
References
- World Health Organization (WHO). WHO Director-General’s opening remarks at the media briefing on COVID-19.
- Coalition for Epidemic Preparedness Innovations (CEPI). 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility.
- Gavi, the Vaccine Alliance. COVAX AMC and Vaccine Portfolio Updates.
